Abstract
The European Network for Cancer Research in Children and Adolescents consortium organized a workshop in Rome, in June 2012, on "Biology-Driven Drug Development Renal Tumors Workshop" to discuss the current knowledge in pediatric renal cancers and to recommend directions for further research. Wilms tumor is the most common renal tumor of childhood and represents a success of pediatric oncology, with cure rates of more than 85% of cases. However, a substantial minority (~25%) responds poorly to current therapies and requires "high-risk" treatment or relapse. Moreover, the successfully treated majority are vulnerable to the late effects of treatment, with nearly one quarter reporting severe chronic health conditions by 25 years of follow-up. Main purposes of this meeting were to advance our understanding on the molecular drivers in Wilms tumor, their heterogeneity and interdependencies; to provide updates on the clinical-pathologic associations with biomarkers; to identify eligible populations for targeted drugs; and to model opportunities to use preclinical model systems and prioritize targeted agents for early phase clinical trials. At least three different pathways are involved in Wilms tumor; this review represents the outcome of the workshop discussion on the WNT/b-catenin pathway in Wilms tumorigenesis.
| Original language | English |
|---|---|
| Pages (from-to) | 2619-2627 |
| Number of pages | 9 |
| Journal | Molecular Cancer Therapeutics |
| Volume | 12 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Dec 2013 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Is wilms tumor a candidate neoplasia for treatment with wnt/β-catenin pathway modulators?-A report from the renal tumors biology-driven drug development workshop. / Perotti, Daniela; Hohenstein, Peter; Bongarzone, Italia; Maschietto, Mariana; Weeks, Mark; Radice, Paolo; Pritchard-Jones, Kathy.
In: Molecular Cancer Therapeutics, Vol. 12, No. 12, 12.2013, p. 2619-2627.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Is wilms tumor a candidate neoplasia for treatment with wnt/β-catenin pathway modulators?-A report from the renal tumors biology-driven drug development workshop
AU - Perotti, Daniela
AU - Hohenstein, Peter
AU - Bongarzone, Italia
AU - Maschietto, Mariana
AU - Weeks, Mark
AU - Radice, Paolo
AU - Pritchard-Jones, Kathy
PY - 2013/12
Y1 - 2013/12
N2 - The European Network for Cancer Research in Children and Adolescents consortium organized a workshop in Rome, in June 2012, on "Biology-Driven Drug Development Renal Tumors Workshop" to discuss the current knowledge in pediatric renal cancers and to recommend directions for further research. Wilms tumor is the most common renal tumor of childhood and represents a success of pediatric oncology, with cure rates of more than 85% of cases. However, a substantial minority (~25%) responds poorly to current therapies and requires "high-risk" treatment or relapse. Moreover, the successfully treated majority are vulnerable to the late effects of treatment, with nearly one quarter reporting severe chronic health conditions by 25 years of follow-up. Main purposes of this meeting were to advance our understanding on the molecular drivers in Wilms tumor, their heterogeneity and interdependencies; to provide updates on the clinical-pathologic associations with biomarkers; to identify eligible populations for targeted drugs; and to model opportunities to use preclinical model systems and prioritize targeted agents for early phase clinical trials. At least three different pathways are involved in Wilms tumor; this review represents the outcome of the workshop discussion on the WNT/b-catenin pathway in Wilms tumorigenesis.
AB - The European Network for Cancer Research in Children and Adolescents consortium organized a workshop in Rome, in June 2012, on "Biology-Driven Drug Development Renal Tumors Workshop" to discuss the current knowledge in pediatric renal cancers and to recommend directions for further research. Wilms tumor is the most common renal tumor of childhood and represents a success of pediatric oncology, with cure rates of more than 85% of cases. However, a substantial minority (~25%) responds poorly to current therapies and requires "high-risk" treatment or relapse. Moreover, the successfully treated majority are vulnerable to the late effects of treatment, with nearly one quarter reporting severe chronic health conditions by 25 years of follow-up. Main purposes of this meeting were to advance our understanding on the molecular drivers in Wilms tumor, their heterogeneity and interdependencies; to provide updates on the clinical-pathologic associations with biomarkers; to identify eligible populations for targeted drugs; and to model opportunities to use preclinical model systems and prioritize targeted agents for early phase clinical trials. At least three different pathways are involved in Wilms tumor; this review represents the outcome of the workshop discussion on the WNT/b-catenin pathway in Wilms tumorigenesis.
UR - http://www.scopus.com/inward/record.url?scp=84890518697&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84890518697&partnerID=8YFLogxK
U2 - 10.1158/1535-7163.MCT-13-0335
DO - 10.1158/1535-7163.MCT-13-0335
M3 - Article
C2 - 24258344
AN - SCOPUS:84890518697
VL - 12
SP - 2619
EP - 2627
JO - Molecular Cancer Therapeutics
JF - Molecular Cancer Therapeutics
SN - 1535-7163
IS - 12
ER -